Literature DB >> 19520493

Sentinel node detection method using contrast-enhanced ultrasonography with sonazoid in breast cancer: preliminary clinical study.

Kiyoka Omoto1, Hiroaki Matsunaga, Natsuki Take, Yasuo Hozumi, Megumi Takehara, Yawara Omoto, Mikio Shiozawa, Hirobumi Mizunuma, Hiroki Harashima, Nobuyuki Taniguchi, Mikihiko Kawano.   

Abstract

This study aimed to evaluate the usefulness of sentinel lymph node (SLN) detection in breast cancer using contrast-enhanced ultrasonography (CEUS) with subareolar Sonazoid injection. The subjects were 20 breast cancer patients. General anesthesia was induced and 2 mL of Sonazoid was injected subareolarly. After massage of the injection site, the axillary area was observed transdermally using coded phase inversion harmonic ultrasonography with mechanical indices of 0.15 to 0.19. When contrast-enhanced lymph nodes (LNs) were seen, they were defined as CE-SLN. Two other SLN detection methods, the gamma-probe-guided and dye-guided methods, were performed together. We evaluated the SLNs detected by each method to determine if they corresponded with each other and calculated the SLN detection rate. After the SLNs were resected, pathologic examinations were done. The SLN detection rate of the CEUS-guided method, the dye-guided method and the gamma-probe-guided method were 70%, 75% and 100%, respectively. There was no statistically significant difference in these rates between the CEUS-guided and dye-guided methods (p = 0.99) but the CEUS-guided method showed a significantly lower rate than the gamma-probe-guided method (p = 0.020), and dye-guided method also showed a significantly lower rate than the gamma-probe-guided method (p = 0.047). The number of CE-SLNs was 1 or 2 (average 1.1) and each took 2 to 20 (average 5.3) min to detect. The CE-SLNs corresponded grossly with SLNs detected by the gamma-probe-guided and dye-guided methods. The pathologic results indicated no metastasis from the resected SLNs in 15 of 20 cases. However, the CEUS-guided method detected 12 cases of these 15 and CE-SLNs were detected in two of the remaining five metastasis cases. In summary, in breast cancer patients, after subareolar injection of Sonazoid, contrast-enhanced LNs were observed in real time with ultrasonography. In an initial clinical study of 20 cases, the detection rate of the CEUS-guided method was less than that of the gamma-probe-guided method. It is suggested that the CEUS-guided method using Sonazoid may, with some improvements, be a useful new modality for sentinel node identification.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520493     DOI: 10.1016/j.ultrasmedbio.2009.02.004

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  25 in total

Review 1.  New ultrasound techniques for lymph node evaluation.

Authors:  Xin-Wu Cui; Christian Jenssen; Adrian Saftoiu; Andre Ignee; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

2.  Perfusion contrast-enhanced ultrasound to predict early lymph-node metastasis in breast cancer.

Authors:  Naoko Mori; Shunji Mugikura; Minoru Miyashita; Yumiko Kudo; Mikiko Suzuki; Li Li; Yu Mori; Shoki Takahashi; Kei Takase
Journal:  Jpn J Radiol       Date:  2018-11-20       Impact factor: 2.374

3.  Contrast-enhanced sonography for detection of secondary lymph nodes in a melanoma tumor animal model.

Authors:  Ji-Bin Liu; Daniel A Merton; Adam C Berger; Flemming Forsberg; Agnieszka Witkiewicz; Hongjia Zhao; John R Eisenbrey; Traci B Fox; Barry B Goldberg
Journal:  J Ultrasound Med       Date:  2014-06       Impact factor: 2.153

4.  Preoperative prediction of sentinel lymph node metastasis in breast cancer based on radiomics of T2-weighted fat-suppression and diffusion-weighted MRI.

Authors:  Yuhao Dong; Qianjin Feng; Wei Yang; Zixiao Lu; Chunyan Deng; Lu Zhang; Zhouyang Lian; Jing Liu; Xiaoning Luo; Shufang Pei; Xiaokai Mo; Wenhui Huang; Changhong Liang; Bin Zhang; Shuixing Zhang
Journal:  Eur Radiol       Date:  2017-08-21       Impact factor: 5.315

5.  Preoperative sentinel lymph node localization in vulvar cancer: preliminary experience with inguinal intradermal contrast-enhanced ultrasound.

Authors:  O Lahtinen; M Eloranta; M Anttila; H Kärkkäinen; R Sironen; R Vanninen; S Rautiainen
Journal:  Eur Radiol       Date:  2017-11-30       Impact factor: 5.315

6.  Enhanced pre-operative axillary staging using intradermal microbubbles and contrast-enhanced ultrasound to detect and biopsy sentinel lymph nodes in breast cancer: a potential replacement for axillary surgery.

Authors:  Karina Cox; Sian Taylor-Phillips; Nisha Sharma; Jennifer Weeks; Philippa Mills; Ali Sever; Adrian Lim; Isobel Haigh; Mohamed Hashem; Tania de Silva; Keshthra Satchithananda; Mengxing Tang; Matthew Wallis
Journal:  Br J Radiol       Date:  2017-12-05       Impact factor: 3.039

Review 7.  New Technologies for Sentinel Lymph Node Detection.

Authors:  Amit Goyal
Journal:  Breast Care (Basel)       Date:  2018-09-18       Impact factor: 2.860

8.  Accurate diagnosis of axillary lymph node metastasis using contrast-enhanced ultrasonography with Sonazoid.

Authors:  Fumihiko Matsuzawa; Takahiro Einama; Hironori Abe; Takashi Suzuki; Jun Hamaguchi; Terumi Kaga; Mami Sato; Masako Oomura; Yumiko Takata; Ayako Fujibe; Chie Takeda; Etsuya Tamura; Akinobu Taketomi; Kenichi Kyuno
Journal:  Mol Clin Oncol       Date:  2014-12-31

9.  Validation of Contrast Enhanced Ultrasound Technique to Wire Localization of Sentinel Lymph Node in Patients with Early Breast Cancer.

Authors:  Maryam H Esfehani; Adel Yazdankhah-Kenari; Ramesh Omranipour; Habib Allah Mahmoudzadeh; Shahriar Shahriaran; Mohammad Reza Zafarghandi; Hadi Ahmadi Amoli
Journal:  Indian J Surg Oncol       Date:  2015-07-18

10.  Assessment of Ultrasound Features Predicting Axillary Nodal Metastasis in Breast Cancer: The Impact of Cortical Thickness.

Authors:  A Stachs; A Tra-Ha Thi; M Dieterich; J Stubert; S Hartmann; Ä Glass; T Reimer; B Gerber
Journal:  Ultrasound Int Open       Date:  2015-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.